Clinical Trial Update: Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine in Indonesian Adults, Adolescents, Children and Infants [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety and immunogenicity of Vi-DT typhoid conjugate vaccine in Indonesian adults, adolescents, children, and infants has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Typhoid Fever

Drugs mentioned

• Vi-DT Typhoid Conjugate Vaccine (Vi-diphtheria toxoid conjugate vaccine)

Snippet

Sponsor: PT Bio Farma | Conditions: Safety Issues, Immunogenicity | Phase 2 | Status: COMPLETED